ReviewBioactive materials2024
SERS sensing for cancer biomarker: Approaches and directions.
Review in Bioactive materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Surface-Enhanced Raman Spectroscopy in Breast Cancer Detection: A Bibliometric Review and Landscape of Global Trends.Biosensors · 2026Review
- Advanced integrated SERS-based strategies for the early diagnosis of upper gastrointestinal cancers.Journal of nanobiotechnology · 2026Review
- Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.Discover nano · 2026Review
- Potential of SERS and proteomics for biomarker detection in cancer cells.Analytical and bioanalytical chemistry · 2026Article
- AI-guided design and biomaterial integration for next-generation extracellular vesicle therapeutics: an evidence-weighted translational framework.Journal of nanobiotechnology · 2026Review
- AI/ML-Assisted SERS Biosensing for Biomolecular Detection: From Direct Spectral Response to Integrated Diagnostic Systems.Biosensors · 2026Review
- Plasmonic and surface-enhanced Raman nanobiosensors for quantitative molecular detection.Discover nano · 2026Review
- Dual electrochemical sensor based on graphene aerogel for quantification of ascorbic acid in pharmaceutical samples and uric acid in urine.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2026Article
- Raman Spectroscopy in Cancer Diagnostics and Surgery: 25 Years of Progress from Surface-Enhanced Raman Spectroscopy to Artificial Intelligence─A Bibliometric and Visualized Study.Analytical chemistry · 2026Review
- Plasmonic glyco-nanoparticles for single-test multiplexed detection and differentiation of cancer cells.Nanoscale · 2026Article
- Mitochondria-Targeted Au@Carbon Dot Nanoprobes for SERS Analysis of Drug-Induced Mitophagy.Chemical & biomedical imaging · 2026Article
- Review
- Simultaneous Electrochemical Formation of Porous Silicon and Noble NPs for Au Nucleation Sites in SERS Substrates.ACS materials Au · 2026Article
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.International journal of molecular sciences · 2026Review
- High reliability Ag/Ni/NiO nanowire-based SERS for cancer detection: a study on breast cancer.Nanoscale advances · 2026Article
- AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Application of surface-enhanced Raman scattering combined with artificial intelligence for multiplex detection of chemotherapeutic agents used in solid tumors.Analytical and bioanalytical chemistry · 2025Article
- Wide-Field Digital Surface-Enhanced Raman Scattering: Quantitative Single-Molecule Detection with High Sensitivity and Throughput.Chemical & biomedical imaging · 2025Article
- Diagnostic oriented discrimination of different Shiga toxins via PCA-assisted SERS-based plasmonic metasurface.Nanophotonics (Berlin, Germany) · 2025Article
- Stimuli-responsive 'On-Off' SERS-darkfield bimodal plasmonic nanoprobes for selective cancer cell illumination.Biosensors & bioelectronics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
These days, cancer is thought to be more than just one illness, with several complex subtypes that require different screening approaches. These subtypes can be distinguished by the distinct markings left by metabolites, proteins, miRNA, and DNA. Personalized illness management may be possible if cancer is categorized according to its biomarkers. In order to stop cancer from spreading and posing a significant risk to patient survival, early detection and prompt treatment are essential. Traditional cancer screening techniques are tedious, time-consuming, and require expert personnel for analysis. This has led scientists to reevaluate screening methodologies and make use of emerging technologies to achieve better results. Using time and money saving techniques, these methodologies integrate the procedures from sample preparation to detection in small devices with high accuracy and sensitivity. With its proven potential for biomedical use, surface-enhanced Raman scattering (SERS) has been widely used in biosensing applications, particularly in biomarker identification. Consideration was given especially to the potential of SERS as a portable clinical diagnostic tool. The approaches to SERS-based sensing technologies for both invasive and non-invasive samples are reviewed in this article, along with sample preparation techniques and obstacles. Aside from these significant constraints in the detection approach and techniques, the review also takes into account the complexity of biological fluids, the availability of biomarkers, and their sensitivity and selectivity, which are generally lowered. Massive ways to maintain sensing capabilities in clinical samples are being developed recently to get over this restriction. SERS is known to be a reliable diagnostic method for treatment judgments. Nonetheless, there is still room for advancement in terms of portability, creation of diagnostic apps, and interdisciplinary AI-based applications. Therefore, we will outline the current state of technological maturity for SERS-based cancer biomarker detection in this article. The review will meet the demand for reviewing various sample types (invasive and non-invasive) of cancer biomarkers and their detection using SERS. It will also shed light on the growing body of research on portable methods for clinical application and quick cancer detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.